H.C. Wainwright raises Teva Pharma stock price target to $54
H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide fresh, material data that can move the stock, especially given the analyst's target increase.
Market read
TEVA's earnings beat and upgraded target are likely to generate buying interest and could lift the broader pharma sector.
What to watch
Potential headwinds from pricing pressures in key markets and upcoming patent expirations are not addressed in the analyst note.
Background
Teva Pharmaceutical Industries reported Q3 2026 results that beat estimates and raised full‑year revenue guidance, prompting H.C. Wainwright to lift its price target.
Ticker impact
H.C. Wainwright raised its price target on Teva to $54 and reported Q3 earnings beat with revenue of $4.395B and EPS $0.86.
likely upward pressure as investors price in the higher target and raised guidance
The price target increase and better‑than‑expected earnings are fresh, material information for a large pharma, prompting traders to consider buying on the upside.
Market effects
The upgrade may lift sentiment across the pharmaceutical sector as peers are re‑priced on stronger earnings trends.
Positive for U.S. large‑cap pharma exposure in the broader market.
Limited to investors tracking global pharma earnings; no direct macro impact.
Counterpoint
If the revenue growth stalls or generic competition intensifies, the higher target could be premature.
Key entities
- companyTeva Pharmaceutical Industries Ltd.
US‑listed pharmaceutical company (NYSE: TEVA) reporting Q3 earnings.
- analyst_firmH.C. Wainwright
Equity research firm that raised its price target on TEVA.
